UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 11, 2004
Eyetech Pharmaceuticals, Inc.
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 000-50516 13-4104684
- ---------------------------- ------------- -------------------
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation) File Numbers) Identification No.)
3 Times Square, 12th Floor
New York, NY 10036
- ---------------------------------------- ----------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (212) 824-3100
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events
On November 11, 2004, Eyetech Pharmaceuticals, Inc. acquired most of the
assets of the Transgenomic, Inc. oligonucleotide manufacturing facility, located
in Boulder, Colorado. The full text of the press release announcing the
acquisition is filed as Exhibit 99.1 to this Current Report on Form 8-K.
The furnishing of the attached press release is not an admission as to the
materiality of any of the information set forth in this Form 8-K or the attached
press release.
The information in this Item 8.01 of Form 8-K (including the exhibit) shall
not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act
of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such a filing.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: November 15, 2004 EYETECH PHARMACEUTICALS, INC.
By: /s/ Glenn P. Sblendorio
----------------------------
Name: Glenn P. Sblendorio
Title: Senior Vice President, Finance
and Chief Financial Officer
EXHIBIT INDEX
Exhibit No. Description
- ----------- -----------
99.1 Press release dated November 8, 2004, of Eyetech Pharmaceuticals,
Inc. announcing the acquisition of most of the assets of the
Transgenomic, Inc. oligonucleotide manufacturing facility,
located in Boulder, Colorado